3 Nasdaq-100 Stocks That Can Double, According to Wall Street

Wall Street median targets imply 100%–140% upside for CoreWeave ($130 vs. $54), Nebius ($300 vs. $150), and Alnylam ($317 vs. $158), but these are analyst price targets, not guaranteed returns. CoreWeave’s Q2 revenue rose 112% to $2.5 billion, while interest expense increased 140% and consumed 25% of sales; Nebius reported 454% revenue growth, though the article states revenue of $582 billion. Alnylam’s Q3 product revenue increased 52% to $1.2 billion, with nucresiran in Phase 3 and a potential 2030 launch. The article highlights growth and upside alongside CoreWeave’s debt burden and Nebius’ expensive valuation.

Analysis

Analyst-target upside is a weak catalyst by itself: target prices are not independent evidence of demand, financing capacity, or clinical success. The more consequential split is between AI-cloud utilization and the cost of funding capacity. CoreWeave’s advantage is execution and technical credibility; its vulnerability is that debt service and GPU depreciation can absorb incremental economics if utilization or pricing softens. Hyperscalers’ commitments support demand, but also fund potential competitors: Meta Platforms and Microsoft can shift workloads in-house or rebalance suppliers, limiting third-party pricing power. Nebius gaining technical standing increases customer choice and raises the risk of price competition; its much richer sales multiple makes it more exposed to any growth deceleration or financing disappointment. Verify Nebius’s reported figures and accounting scope before using them in a relative-value model—the article’s revenue figure appears suspect.

Alnylam offers a different risk profile: current product growth is concentrated in its TTR franchise, so pipeline breadth should not be valued as if already commercial. Nucresiran could extend the franchise, but a later launch and potential substitution for existing products make the net incremental revenue—not just efficacy or dosing convenience—the key variable. Over 1–3 months, monitor AI-cloud bookings, utilization, financing terms, and guidance; over 6–18 months, watch capacity returns and TTR franchise mix. Falsifiers include worsening CoreWeave operating cash generation or rising funding costs, Nebius growth/margins missing expectations, and Alnylam TTR growth slowing or clinical/regulatory setbacks.

Key Decisions for Investors

• Do not trade the advertised target-price upside as a catalyst. For AI exposure, prefer a staged CoreWeave position over Nebius on relative valuation and execution grounds, but size it as a high-volatility, leveraged infrastructure exposure. Reassess if operating cash generation weakens, interest burden rises, or utilization and pricing deteriorate.
• Keep Nebius on a watchlist rather than chase the growth narrative at its stated premium. Consider a relative-value short only after verifying the financial data, share count, financing commitments, and comparable forward-sales assumptions; the thesis is multiple compression on deceleration, not a claim that demand disappears.
• For a lower-correlation growth sleeve, consider a modest Alnylam position, contingent on confirming TTR product growth and the commercial opportunity for nucresiran. Track franchise concentration and whether new-product uptake adds to, rather than merely replaces, existing sales; reduce exposure on material Phase 3, regulatory, or guidance setbacks.
• Near-term catalyst checklist: AI provider disclosures on backlog conversion, utilization, capex funding and customer concentration; and Alnylam trial updates plus product-level revenue mix. Avoid extrapolating company-level growth rates into durable margins without those checks.